36716-71-9

Usage

Uses

Used in Organic Synthesis:
4-(4-Chlorophenyl)-4-hydroxycyclohexanone is used as a key intermediate in the synthesis of various organic compounds. Its chemical structure allows it to participate in a range of reactions, such as condensation, substitution, and rearrangement, which are crucial for the development of new molecules with specific properties and applications.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 4-(4-Chlorophenyl)-4-hydroxycyclohexanone is used as a building block for the development of novel drugs. Its unique structure can be modified and functionalized to create new drug candidates with potential therapeutic applications.
Used in Chemical Research:
4-(4-Chlorophenyl)-4-hydroxycyclohexanone is also employed in chemical research as a model compound to study various reaction mechanisms and to develop new synthetic methodologies. Its reactivity and structural features make it an ideal candidate for exploring new chemical transformations and understanding the underlying principles of organic chemistry.
Used in Material Science:
In the field of material science, 4-(4-Chlorophenyl)-4-hydroxycyclohexanone can be used as a precursor to develop new materials with specific properties, such as improved stability, enhanced reactivity, or tailored physical characteristics. Its versatility in organic synthesis allows for the creation of a wide range of materials with potential applications in various industries.

InChI:InChI=1/C12H13ClO2/c13-10-3-1-9(2-4-10)12(15)7-5-11(14)6-8-12/h1-4,15H,5-8H2

Upstream product

• 126991-59-1 8-(4-chlorophenyl)-1,4-dioxaspiro[4.5]decan-8-ol 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 106-39-8 bromochlorobenzene 
• 13482-22-9 4-hydroxycyclohexanone 
• 873-77-8 (4-chlorphenyl)magnesium bromide 
• 637-87-6 1-Chloro-4-iodobenzene 

Downstream Products

• 73330-74-2 4-(p-Chlorophenyl)-4-hydroxycyclohexanone O-methyloxime 
• 73330-73-1 4-(p-Chlorophenyl)-4-hydroxycyclohexanone oxime 
• 14472-80-1 4-(4-chlorophenyl)cyclohexan-1-one 
• 36716-78-6 4-(p-chlorophenyl)-3-cyclohexen-1-ol 
• 36716-82-2 Methanesulfonic acid 4-(4-chloro-phenyl)-cyclohex-3-enyl ester 
• 1071223-07-8 cis-2-[4-(4-chlorophenyl)cyclohexyl]-3-chloro-1,4-naphthoquinone 
• 215672-87-0 Oxalic acid mono-[4-(4-chloro-phenyl)-cyclohexyl] ester 
• 98322-65-7 4-(4-Chloro-phenyl)-cyclohexanol 
• 42020-44-0 4-(p-chlorophenyl)-4-hydroxycyclohexanone dimethyl ketal 

Relevant academic research and scientific papers

All-benzene carbon nanocages: Size-selective synthesis, photophysical properties, and crystal structure

The design and synthesis of a series of carbon nanocages consisting solely of benzene rings are described. Carbon nanocages are appealing molecules not only because they represent junction unit structures of branched carbon nanotubes, but also because of their potential utilities as unique optoelectronic π-conjugated materials and guest-encapsulating hosts. Three sizes of strained, conjugated [n.n.n]carbon nanocages (1, n = 4; 2, n = 5; 3, n = 6) were synthesized with perfect size-selectivity. Cyclohexane-containing units and 1,3,5-trisubstituted benzene-containing units were assembled to yield the minimally strained bicyclic precursors, which were successfully converted into the corresponding carbon nanocages via acid-mediated aromatization. X-ray crystallography of 1 confirmed the cage-shaped structure with an approximately spherical void inside the cage molecule. The present studies revealed the unique properties of carbon nanocages, including strain energies, size-dependent absorption and fluorescence, as well as unique size-dependency for the electronic features of 1-3.

4-AZETIDINYL-1-PHENYL-CYCLOHEXANE ANTAGONISTS OF CCR2

The present invention comprises compounds of Formula (I): wherein: X, R1, R2, R3, and R4 are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

Synthesis of atovaquone

A short synthesis of atovaquone I is achieved via the radical coupling of the trans-1,4-substituted cyclohexyl mono-oxalate 2 and 2- chloronapthoquinone under phase transfer conditions.

4'-Fluoro-4-{[4-(phenyl)cyclohexyl]amino}butyrophenones and the salts thereof

This invention relates to novel 4-phenylcyclohexylamines embraced by the formula SPC1 Wherein ? is a generic expression denoting cis and trans stereoconfiguration and mixtures thereof; R is selected from the group consisting of alkyl of from one through four carbon atoms, fluorine, chlorine, bromine, trifluoromethyl, nitro and alkoxy of from one through four carbon atoms; R' and R1 are selected from the group consisting of hydrogen and alkyl of from one through four carbon atoms; R2 is selected from the group consisting of hydrogen, alkyl of from one through four carbon atoms, alkanoyl of from one through three carbon atoms, alkylsulfonyl of from one through three carbon atoms, arylsulfonyl of from six through ten carbon atoms, alkylcarbamoyl wherein alkyl is from one through four carbon atoms, alkoxycarbonyl wherein alkyl is from one through four carbon atoms, ring monosubstituted aroylalkyl wherein the substituents have the same meaning as R, above, aryl is from six through ten carbon atoms and alkyl is from one through six carbon atoms and bis (ring monosubstituted) arylalkyl wherein the substituents have the same meaning as R, above, aryl is from six through ten carbon atoms and alkyl is from one through six carbon atoms; R1 and R2 when taken together with --N is a saturated heterocyclic amino radical selected from the group consisting of unsubstituted and monosubstituted pyrrolidino, piperidino, hexamethylenimino, morpholino and piperazino; and an acid addition salt thereof. It also relates to intermediates and processes for the preparation of the aforesaid novel compounds (1) and novel derivatives thereof. The systemic administration to humans and animals of the novel compounds (1) depresses their central nervous systems.

4'-Fluoro-4-{[4-(phenyl)-4-alkoxy-cyclo-hexyl]amino}butyrophenones and the salts thereof

This invention relates to novel 4-(substituted alkoxy)-4-(substituted phenyl)cyclohexylamines embraced by the formula SPC1 Wherein ? is a generic expression denoting cis and trans stereoconfiguration and mixtures thereof, with the proviso that when the st